Marksans Pharma Falls 8.67%: Valuation and Technical Shifts Define the Week
2026-11-21 17:00:40Key Events This Week 16 Nov: Upgrade to Buy on strong financials and bullish technicals 16 Nov: Technical momentum shifts signal bullish outlook 19 Nov: Downgrade to Hold amid mixed technicals and expensive valuation 19 Nov: Valuation shifts reflect changing market sentiment 20 Nov: Week closes at Rs.290.90 (-8.67%) vs Sensex +1.55% Week Open ...
Read More
Marksans Pharma Ltd Valuation Shifts Signal Changing Market Sentiment
2026-11-19 08:00:32Marksans Pharma Ltd has seen its valuation grade revised from very expensive to expensive, reflecting a notable shift in price attractiveness despite robust long-term returns. The pharmaceutical company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios indicate a premium valuation relative to historical averages and peer benchmarks, prompting a reassessment of its investment appeal.
Read More
Marksans Pharma Upgraded to Buy on Strong Financials and Bullish Technicals
2026-11-16 08:35:16Marksans Pharma Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, announced on 13 Nov 2026, comes amid robust quarterly results, a bullish technical outlook, and sustained long-term outperformance relative to the broader market.
Read More
Marksans Pharma Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-11-16 08:02:18Marksans Pharma Ltd has recently experienced a notable shift in its technical momentum, with key indicators signalling an upgrade from a mildly bullish to a bullish trend. This change, coupled with a strong fundamental backdrop and impressive long-term returns, positions the small-cap pharmaceutical company favourably amid a volatile market environment.
Read More
Marksans Pharma Ltd is Rated Buy
2026-11-15 10:10:29Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 13 November 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 November 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read More
Marksans Pharma Ltd Reports Positive Quarterly Performance Amid Margin Expansion
2026-11-05 08:00:29Marksans Pharma Ltd has delivered a robust quarterly performance for September 2026, registering record net sales and profit before depreciation, interest and taxes (PBDIT), alongside a significant rise in profit after tax (PAT). Despite a recent downgrade in its Mojo Grade from Buy to Hold, the company’s financial trajectory remains positive, reflecting strong operational execution amid evolving margin dynamics.
Read More
Marksans Pharma Ltd is Rated Buy by MarketsMOJO
2026-11-04 10:11:29Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Marksans Pharma Ltd is Rated Buy by MarketsMOJO
2026-10-24 10:10:39Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Marksans Pharma Ltd is Rated Buy
2026-10-13 10:10:56Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 October 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
13-Nov-2026 | Source : BSETranscript of Investors/Analyst meet on Q2 FY27 Financial Results
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
05-Nov-2026 | Source : BSEAudio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results
Announcement under Regulation 30 (LODR)-Newspaper Publication
05-Nov-2026 | Source : BSENewspaper Publication for Unaudited Financial Results for the quarter and half year ended September 30 2026
Corporate Actions
No Upcoming Board Meetings
Marksans Pharma Ltd has declared 90% dividend, ex-date: 20 Aug 26
Marksans Pharma Ltd has announced 1:10 stock split, ex-date: 11 Mar 08
No Bonus history available
No Rights history available